Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy

(2019) Erlend Skaga et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

(2019) Marc‐Eric Halatsch et al.   BRITISH JOURNAL OF PHARMACOLOGY

HIV-1 Drug Resistance Mutations among Antiretroviral Drug-Experienced Patients in the South of Iran

(2019) Arash Memarnejadian et al.   INTERVIROLOGY

Reversal of the Warburg effect with DCA in PDGF‑treated human PASMC is potentiated by pyruvate dehydrogenase kinase‑1 inhibition mediated through blocking Akt/GSK‑3β signalling

(2018) Bingbing Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells

(2018) Carsten Pelz et al.   CELLULAR ONCOLOGY

Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping

(2017) Xiaofeng Dai et al.   Journal of Cancer

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

(2017) R. Tibes et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation

(2016) Rebecca H. Chisholm et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction

(2016) Agostinho Lemos et al.   MEDICINAL RESEARCH REVIEWS

Optimization of drug combinations using Feedback System Control

(2016) Patrycja Nowak-Sliwinska et al.   Nature Protocols

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

(2015) Andrea Weiss et al.   ANGIOGENESIS

Large-scale exploration and analysis of drug combinations

(2015) Peng Li et al.   BIOINFORMATICS

The Anatomy of Medical Research

(2015) Hamilton Moses et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide

(2015) Richard E. Kast et al.   Oncotarget

A streamlined search technology for identification of synergistic drug combinations

(2015) Andrea Weiss et al.   Scientific Reports

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

(2014) M. I. Gross et al.   MOLECULAR CANCER THERAPEUTICS

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways

(2014) S J Allison et al.   Oncogenesis

Primary and secondary distant metastatic breast cancer: Two sides of the same coin

(2013) Uwe Güth et al.   BREAST

Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor

(2013) Emilia C. Calvaresi et al.   CHEMBIOCHEM

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination

(2010) Hanna Berglind et al.   CANCER BIOLOGY & THERAPY

Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α

(2009) Yoon-Mi Lee et al.   CARCINOGENESIS

6-Shogaol, an Active Constituent of Dietary Ginger, Induces Autophagy by Inhibiting the AKT/mTOR Pathway in Human Non-Small Cell Lung Cancer A549 Cells

(2009) Jen-Yu Hung et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Preclinicalversusclinical drug combination studies

(2008) Ting-Chao Chou   LEUKEMIA & LYMPHOMA

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 

(2008) M. Y. Koh et al.   MOLECULAR CANCER THERAPEUTICS